Animal Models for Bladder Cancer: The Model Establishment and Evaluation (Review)

Overview

Journal Oncol Lett

Specialty Oncology

Date 2015 Mar 20

PMID 25788992

Citations 20

Authors

Ning Zhang

Dongyang Li

Jialiang Shao

Xiang Wang

Affiliations

Soon will be listed here.

Abstract

Bladder cancer is the most common type of tumor in the urogenital system. Approximately 75% of patients with bladder cancer present with non-muscle-invasive cancer, which is generally treated by transurethral resection and intravesical chemotherapy. In spite of different therapeutic options, there remains a very variable risk of recurrence and progression. Novel therapeutic methods of treating bladder cancer are urgently required. The exploration and preclinical evaluation of new treatments requires an animal tumor model that mimics the human counterpart. Animal models are key in bladder cancer research and provide a bridge to the clinic. Various animal bladder cancer models have been described to date, but the tumor take rate is reported to be 30-100%. Establishment of reliable, simple, practicable and reproducible animal models remains an ongoing challenge. The present review summarizes the latest developments with regard to the establishment of animal models and tumor evaluation.

Citing Articles

Pigs: Large Animal Preclinical Cancer Models.

Joshi K, Katam T, Hegde A, Cheng J, Prather R, Whitworth K World J Oncol. 2024; 15(2):149-168.

PMID: 38545477 PMC: 10965265. DOI: 10.14740/wjon1763.

Circular STAG2 RNA Modulates Bladder Cancer Progression via miR-145-5p/TAGLN2 and Is Considered as a Biomarker for Recurrence.

Du C, Waltzer W, Wilusz J, Spaliviero M, Darras F, Romanov V Cancers (Basel). 2024; 16(5).

PMID: 38473339 PMC: 10930502. DOI: 10.3390/cancers16050978.

Establishment of Mouse Orthotopic Urinary Bladder Tumor Model and Its Analysis by Light and Electron Microscopy.

Erman A, Kamensek U, Peskar D, Veranic P Methods Mol Biol. 2024; 2773:33-49.

PMID: 38236534 DOI: 10.1007/978-1-0716-3714-2_4.

Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs.

Rangel M, Linhares L, de Oliveira K, Suzuki D, Maglietti F, De Nardi A Sci Rep. 2023; 13(1):21078.

PMID: 38030630 PMC: 10687251. DOI: 10.1038/s41598-023-45433-4.

Effects of Scaffolds on Urine- and Urothelial Carcinoma Tissue-Derived Organoids from Bladder Cancer Patients.

Walz S, Pollehne P, Vollmer P, Aicher W, Stenzl A, Harland N Cells. 2023; 12(16).

PMID: 37626918 PMC: 10453567. DOI: 10.3390/cells12162108.

References

Cohen S, Ohnishi T, Arnold L, Le X . Arsenic-induced bladder cancer in an animal model. Toxicol Appl Pharmacol. 2006; 222(3):258-63. DOI: 10.1016/j.taap.2006.10.010. View

Ayala de la Pena F, Kanasaki K, Kanasaki M, Tangirala N, Maeda G, Kalluri R . Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem. 2011; 286(23):20778-87. PMC: 3121487. DOI: 10.1074/jbc.M110.198069. View

Wu X . Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer Metastasis Rev. 2009; 28(3-4):281-90. PMC: 2797413. DOI: 10.1007/s10555-009-9189-4. View

Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P . Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012; 63(2):234-41. DOI: 10.1016/j.eururo.2012.07.033. View

Chan E, Patel A, Heston W, Larchian W . Mouse orthotopic models for bladder cancer research. BJU Int. 2009; 104(9):1286-91. DOI: 10.1111/j.1464-410X.2009.08577.x. View

Grivas P, Day K, Karatsinides A, Paul A, Shakir N, Owainati I . Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer. Mol Med. 2013; 19:367-76. PMC: 3883970. DOI: 10.2119/molmed.2013.00108. View

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-403. DOI: 10.1016/j.ejca.2012.12.027. View

Yu D, Lee C, Chang S . Immunotherapy for orthotopic murine bladder cancer using bacillus Calmette-Guerin recombinant protein Mpt-64. J Urol. 2007; 177(2):738-42. DOI: 10.1016/j.juro.2006.09.074. View

Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T . Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 2009; 15(2):114-23. PMC: 2673504. DOI: 10.1016/j.ccr.2008.12.018. View

10.

Zhang T, Fan J, Wu K, Zeng J, Sun K, Guan Z . Roles of HIF-1α in a novel optical orthotopic spontaneous metastatic bladder cancer animal model. Urol Oncol. 2012; 30(6):928-35. DOI: 10.1016/j.urolonc.2012.01.003. View

11.

Mangsbo S, Ninalga C, Essand M, Loskog A, Totterman T . CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J Immunother. 2007; 31(1):34-42. DOI: 10.1097/CJI.0b013e3181587d29. View

12.

Ahmad I, Sansom O, Leung H . Exploring molecular genetics of bladder cancer: lessons learned from mouse models. Dis Model Mech. 2012; 5(3):323-32. PMC: 3339826. DOI: 10.1242/dmm.008888. View

13.

Lodillinsky C, Rodriguez V, Vauthay L, Sandes E, Casabe A, Eijan A . Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer. J Urol. 2009; 182(2):749-55. DOI: 10.1016/j.juro.2009.03.076. View

14.

Wang Y, Revelo M, Sudilovsky D, Cao M, Chen W, Goetz L . Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate. 2005; 64(2):149-59. DOI: 10.1002/pros.20225. View

15.

Knapp D, Glickman N, DeNicola D, Bonney P, Lin T, Glickman L . Naturally-occurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancer. Urol Oncol. 2011; 5(2):47-59. DOI: 10.1016/s1078-1439(99)00006-x. View

16.

Babjuk M, Burger M, Zigeuner R, Shariat S, van Rhijn B, Comperat E . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64(4):639-53. DOI: 10.1016/j.eururo.2013.06.003. View

17.

Smith E, Schwartz M, Kawamoto H, You X, Hwang D, Liu H . Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol. 2007; 177(6):2347-51. DOI: 10.1016/j.juro.2007.01.112. View

18.

Spry L, Zenser T, Cohen S, Davis B . Role of renal metabolism and excretion in 5-nitrofuran-induced uroepithelial cancer in the rat. J Clin Invest. 1985; 76(3):1025-31. PMC: 423976. DOI: 10.1172/JCI112055. View

19.

Williams P, Lee J, Theodorescu D . Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia. 2008; 10(8):838-46. PMC: 2481571. DOI: 10.1593/neo.08432. View

20.

van der Horst G, van Asten J, Figdor A, van den Hoogen C, Cheung H, Bevers R . Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis. Eur Urol. 2011; 60(2):337-43. DOI: 10.1016/j.eururo.2011.05.005. View